Aldeyra Therapeutics Inc (NASDAQ: ALDX) has received a Complete Response Letter from the FDA for the 505(b)(2) New Drug Application (NDA) of ADX-2191 (methotrexate for injection) for
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, June 15, 2023, at 8:00 a.m. (ET) to provide top-line results from the Phase 3 INVIGORATE‑2 Trial
ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) shares traded higher on Thursday. The stock brushed off losses made earlier in the week to continue its recent head-turning uptrend.